GSK Expands Neuroscience Ventures with Muna Therapeutics for Alzheimer's Research

GlaxoSmithKline (GSK) has secured an important collaboration with Danish biotech startup Muna Therapeutics to pursue new therapies for Alzheimer's disease[1][2][3]. Through this partnership, GSK gains access to Muna's innovative MiND-MAP platform, which analyzes postmortem brain tissues using single-cell spatial multi-omics and bioinformatics to identify Alzheimer’s disease targets[1][3]. GSK has committed an upfront payment of €33.5 million, with milestone payments up to €140 million for each identified target, alongside royalties from potential future product sales[1][2]. This collaboration is part of GSK's broader strategy to reinvest in neuroscience, highlighted by other recent agreements targeting neurodegenerative conditions[2][3].